tiprankstipranks
Trending News
More News >

Ligand announces completion of Pelthos Therapeutics merger with Channel

Ligand (LGND) Pharmaceuticals announced the completion of its previously announced merger between the company’s wholly owned subsidiary, LNHC and CHRO Merger Sub, a wholly owned subsidiary of Channel Therapeutics Corporation. The combined company will operate under the name Pelthos Therapeutics and will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1